Novel Formulation Bases and Pre-clinical Trial Results for Rx Drug Candidates
CanaQuest Medical is a clinical-stage life sciences company focused on the drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors.
CanaQuest is collaborating with multiple Canadian universities including a Western University team led by Dr. Steven Laviolette, who has decades of research experience focused on novel pharmacotherapies to treat neurological conditions, such as anxiety, depression, schizophrenia, and Post Traumatic Stress Disorder “PTSD”, including addiction.
Dr. Laviolette’s team has made two amazing drug candidate discoveries, Rx CQ-001 (CBD molecules + formula) and Rx CQ-002 (THC molecules + formula), for treating mental ailments. Pre-clinical trials completed – setting the stage for pre-approved clinical trials.
To learn more about our value proposition and our pre-approved clinical trials, view our Corporate Presentation by clicking the thumbnail graphic further down.
2021 Global Excellence Awards
Best Medical Cannabis and Botanical Oils Product Development Company, 2021 – North America
Awarded by Global Health & Pharma, UK
Corporate Presentation
Our corporate introduction document provides a comprehensive summary of CanaQuest today and its many opportunities for the future.
Click picture above to see the full presentation.
Drug Candidate Formulations
CanaQuest is primed to realize the infinite potential of targeted therapeutics within the endocannabinoid system and specific brain receptors to mediated signaling pathways.
CQ-001, Drug Candidate – Epilepsy
(CBD molecules + formula)
Clinical-trial stage
Supports anxiety, depression, schizophrenia, PTSD and addiction
CQ-002, Drug Candidate – Safer alternative
(THC molecules + formula)
Clinical-trial stage
Supports mental health: safer alternative to THC by itself
CQ-003, Drug Candidate – Pain
(CBD molecules + formula)
In development
To support inflammation & pain
CQ-004, Drug Candidate – Alzheimer’s
(THC + CBD molecules + formula)
In development
To support mental health
FOCUS AREAS
Anxiety
Addiction
Depression
Schizophrenia
PTSD
Chronic Pain
OUR VISION
Our vision is to be a global leader in the formulation and development of medicine derived from cannabinoids and other botanical-based molecules.
IN THE NEWS
CanaQuest Files International Mentanine(R) Patent, a Scientific CBD Formulation for Mental Health
TORONTO, ON / April 29, 2021 -- CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the "Company" or "CanaQuest"), an award-winning Life Science/Pharmaceutical company developing formulations combining cannabinoid molecules with pharmaceutical-grade botanical compounds, today announced the filing of its International [...]
CanaQuest Medical Corp Appoints Investor Relations and PR Veteran Rob Rinderman as its New Director of Communications
TORONTO, ON / April 7, 2021 -- CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the "Company" or "CanaQuest"), an award-winning Life Science/Pharmaceutical company developing health and wellness products combining cannabinoid molecules with pharmaceutical-grade botanical compounds, today announced that Rob Rinderman [...]
CanaQuest Medical Corp Honored With International CBD Life Science R & D Excellence Award 2020 by Global Health & Pharma
TORONTO, ON / March 30, 2021 -- CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the "Company" or "CanaQuest"), a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), today announced it has been [...]